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a  b  s  t  r  a  c  t
Rotarix®,  a vaccine  for the  prevention  of gastroenteritis  in  young  children,  was  introduced  in England
in  July  2013.  At around  this  time,  an  elevated  risk  of  intussusception  (a cause  of  bowel  obstruction)  was
reported  among  infants  vaccinated  in Australia  and  the  USA.  A risk-beneﬁt  analysis  compared  potential
vaccine-related  risks  (additional  intussusception  admissions  and  deaths)  with  estimated  vaccine  beneﬁts
(prevented  rotavirus  general  practitioner  visits,  emergency  visits,  admissions  and  deaths)  in  the  2012
birth  cohort.  Detailed  data  from  England  included  the incidence  of  intussusception  events  aged  <2  years
by week  of  age,  the  coverage  of  vaccination  aged  <2 years  by  week  of age,  and  the  incidence  of  rotavirus
gastroenteritis  (RVGE)  events  aged  <5 years  by week  of  age.  Recent  estimates  of  vaccine-related  risk  from
Australia  were  applied  during  the  1–21  day  period  after  the ﬁrst and  second  dose  of vaccination.  Rotarix®
is estimated  to cause  one  additional  intussusception  admission  in  every  18,551  vaccinated  English  infants
(5th  and  95th  percentiles,  6728–93,952),  equivalent  to 35  (7-98) additional  intussusception  admissions
each  year.  The  vaccine  is  estimated  to prevent  three  rotavirus  deaths,  13,000  rotavirus  admissions,  27,000
rotavirus emergency  visits  and  74,000  rotavirus  GP  consultations  in  children  aged  <5  years,  and  lead  to
annual  savings  of  over  £11  million,  each  year.  We  estimate  375  (136-1900)  fewer  RVGE admissions
for  every  additional  intussusception  admission,  and  88  (18-852)  fewer  RVGE  deaths  for every  additional
intussusception  death.  The  estimated  beneﬁts  of  Rotarix® vaccination  would  greatly  exceed the  potential
risk  in  England.. Introduction
Rotavirus is a leading cause of childhood diarrhoea in England.
lthough less than ﬁve children are estimated to die from rotavirus
astroenteritis (RVGE) each year [1], it is a common and painful
llness and causes anxiety for parents. RVGE also represents a signif-
cant economic burden; one in seven English newborns will require
 visit to their general practitioner (GP) before their 5th birthday,
ne in 22 will visit Accident and Emergency (A&E) and one in 45 will
e admitted to hospital. The estimated cost to the English National
ealth Service (NHS) is over ten million pounds annually [2].
Rotarix® (GlaxoSmithKline), a vaccine for the prevention of
evere RVGE in young children, was introduced in England in July
∗ Corresponding author at: London School of Hygiene and Tropical Medicine, 15-
7  Tavistock Place, London WC1H 9SH, UK.
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ttp://dx.doi.org/10.1016/j.vaccine.2014.04.082
264-410X/© 2014 Published by Elsevier Ltd.© 2014  Published  by Elsevier  Ltd.
2013 [3]. The vaccine is administered orally, and is given in two
doses at two  and three months of age. The decision to introduce
Rotarix® was made by the Department of Health in November 2012
after it became possible to procure the vaccine at a cost-effective
price [4]. The Joint Committee on Vaccination and Immunisa-
tion (JCVI) had previously reviewed studies showing that Rotarix®
would not be cost-effective unless priced at £19 per dose (£38 per
course) or lower [5,6]. At this price each year of full health gained by
vaccination would cost the Government £30,000, the upper limit
accepted by the National Institute for Health and Care Excellence
(NICE) [7].
A randomised controlled trial of Rotarix® in six European
countries reported vaccine efﬁcacy of 90% against severe RVGE
[8] and several high income countries, including Finland, Australia
and the USA, have now introduced the vaccine with impressive
declines in childhood rates of gastroenteritis [9]. There have how-
ever been concerns about the safety of rotavirus vaccines; the ﬁrst
rotavirus vaccine, RotaShield®, was  withdrawn from the market
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fter an association was found that was consistent with it caus-
ng intussusception, a rare bowel disorder, in one in every 4670 to
474 infants vaccinated in the USA [10]. Intussusception, when the
owel telescopes into itself, is the most common cause of bowel
bstruction in young infants. Large safety trials of both new vac-
ines, Rotarix® and Rotateq® (Merck) were able to exclude the
evel of risk associated with RotaShield® [11,12], but were not
owered to exclude a lower level of risk. The level of risk that
ay  turn out to be associated with Rotarix® in England is difﬁ-
ult to predict. However recent post-licensure data from two other
igh income settings, the USA and Australia, indicates a risk of one
accine-related intussusception case in every 20,000 vaccinated
nfants [13]. This overall estimate is not directly comparable to the
isk reported for RotaShield® because the new vaccines have been
dministered within age restrictions designed to avoid the peak age
f intussusception.
If left untreated, intussusception is a fatal condition. However,
n England, where most children have access to timely health care,
ewer than 0.5% of cases are estimated to die, and most cases
ill have an uneventful recovery following enema reduction or
urgery [14]. That Rotarix® continues to be used in all settings
here an elevated intussusception risk has been detected (USA,
ustralia, Mexico, Brazil) implies that the beneﬁts are considered
o greatly outweigh this risk [13]. The World Health Organisa-
ion (WHO) has taken a similar position by recommending the
lobal use of rotavirus vaccines despite their small known risk
f intussusception, and has further recommended the removal of
ge restrictions in countries with delayed vaccination and high
VGE mortality, so that more children can receive the beneﬁts of
he vaccine [15,16]. These age restrictions are designed to ensure
he vaccine is administered before the peak age of intussuscep-
ion. In England, where vaccination is timely and RVGE mortality is
ow, health practitioners have been given clear advice to adhere to
hese age restrictions (ﬁrst dose of Rotarix® given no later than
5 weeks and second dose of Rotarix® no later than 24 weeks)
4].
In England, the potential risk of vaccine-related intussusception
s unlikely to become clear until at least 18 months after Rotarix®
s introduced when the expected number of cases in the absence of
 risk would be about two in the week after the ﬁrst dose and ﬁve
ases in the week after the second dose. In the interim, we  aim to
stimate the potential burden of vaccine-related intussusceptions
ach year, and try to balance this against the estimated health ben-
ﬁts of the vaccine. The aim of this analysis is not to alarm parents
nd health professionals about the, as yet unknown, risk of intus-
usception in England; rather we aim to help put the potential risk
n context, so that both parents and policy makers can make an
nformed judgement about Rotarix® vaccination.
. Methods
An Excel-based [17] cohort model with a ﬁnely disaggregated
ge structure (weekly to age one year, and monthly to age ﬁve
ears) was used to estimate the risks and beneﬁts of Rotarix® vac-
ination in England. All parameter values, and uncertainty ranges
re listed in Table 1.
.1. Estimated risks of Rotarix® (additional intussusception
vents)Previously described methods [15] were adapted to account for
he two periods of risk (1–7 days and 8–21 days) following both the
rst and second dose. For each dose, the number of vaccine-related
ntussusception cases was calculated as follows: (2014) 3604–3610 3605
PY × (Cw − Cw−1) number of new doses given in
week of age
×
[Iw × (RR1–7 − 1) incidence of vaccine-related
intussusception cases in 1–7
day risk period
+
Iw+1 × (RR8–21 − 1) incidence of vaccine-related
intussusception cases in 8–14
day risk period
+
Iw+2 × (RR8–21 − 1)] incidence of vaccine-related
intussusception cases in 15–21
day risk period
where PY, mid-year population for single year of age (i.e. either
<12 m or 12–23 m population); Cw, cumulative coverage estimate
for the week of age; Cw−1, cumulative coverage estimate for
the week preceding the current week of age; Iw, background
incidence of intussusception in week 1 after vaccination (1–7
days); Iw+1, background incidence of intussusception in week
2 after vaccination (8–14 days); Iw+2, background incidence of
intussusception in week 3 after vaccination (15–21 days); RR1–7,
relative risk of vaccine-related intussusception versus background
intussusception during the 1–7 day period after vaccination;
RR8–21, relative risk of vaccine-related intussusception versus
background intussusception during the 8–21 day period after
vaccination.
Mid-2012 population estimates for England were 696,400 (<12
months) and 684,000 (12–23 months) [18].
Vaccination coverage of DTP3 was estimated to be 94.7% by age
12 months and 96.4% at 24 months in England during the last quar-
ter of 2012 [19]. Coverage of DTP1 and DTP2 (proxies for coverage
of Rotarix® dose 1 and 2) are not routinely reported. We  therefore
applied a 2% drop-out rate between the 1st (99%) and 3rd (97%)
primary dose, as reported by WHO-UNICEF for the United King-
dom in 2012 [20], to give DTP1 coverage of 98.4% (99/97 × 96.4%)
at 24 months. We assumed DTP2 coverage would be 97.4% at 24
months, half-way between DTP1 and DTP3 coverage. Coverage at
12 months was  estimated to be 97.8% for DTP1 and 96.3% for DTP2
by assuming one-third and two-thirds respectively, of the relative
difference between 12 and 24 month coverage reported for DTP3.
We assumed Rotarix® would have the same delays in adminis-
tration as the ﬁrst two doses of DTP (Diphtheria-Tetanus-Pertussis).
DTP1 and DTP2 timeliness was estimated by week of age for a sam-
ple of children (n = 37,046) born in the year 2010 from child health
information systems covering 14 different regions of England
(Avon, South Birmingham, Buckinghamshire, Chesterﬁeld, Devon,
Dorset, Dudley, Herefordshire, Kent, Manchester, Northampton,
Stafford, Walsall, Warwickshire) [19]. Age restrictions were applied
to the base case scenario; coverage was truncated at 15 weeks of age
for dose one and 24 weeks of age for dose two  (dose two coverage
could not exceed dose one coverage).
The background age-speciﬁc incidence of intussusception in
England was  based on Hospital Episode Statistics (HES) for chil-
dren aged <2 years, pooled for the 10.75 year period between April
2002 and December 2012 [21]. Incidence of intussusception was
relatively stable in this age group over the period so numbers of
cases in each week were divided by 10.75 to estimate weekly inci-
dence in a single calendar year. A gamma  distribution (mean 30.8,
standard deviation 14.2 and shift −0.36) was ﬁtted to the age dis-
tribution. The estimated annual incidence of intussusception was
28.1 (95% CI: 24.1–32.3) per 100,000 children aged <12 months, and
18.0 (95% CI: 15.8–20.4) per 100,000 children aged <2 years, based
on mid-2008 populations of 667,568 and 1307,342 respectively. On
average, each year there were 187 intussusception hospital admis-
sions aged <12 months and 48 admissions aged 12–23 months.
The risk of vaccine-related intussusception is not yet known for
England, but is likely to be closer to the situation in the USA and
3606 A. Clark et al. / Vaccine 32 (2014) 3604–3610
Table 1
Parameters and probability distributions used for Monte Carlo simulations.
Parameter Base case (95% CI) Probability distribution Reference
Incidence of RVGE events per 1000 birthsa
RVGE GP visits 28.4 (25.7–31.1) Normal (m = 28.4, sd = 1.38) [2]
RVGE A+E visits 9.3 (7.3–11.3) Normal (m = 9.3, sd = 1.02) [2]
RVGE Admissions 4.5 (4.3–4.7) Normal (m = 4.5, sd = 0.1) [2]
Number of RVGE deaths per yeara
RVGE deaths 3.3 (1.7–4.9) Normal (m = 3.3, sd = 0.84) [2]
Incidence of Intussusception per 100,000 per yeara
Incidence of Intussusception <2yrs 18.0 (15.8–20.4) Gamma  (scale = 235.8, shape = 0.08) [21]
Case fatality ratio of intussusception
Intussusception CFR 0.12% (0.02–0.34) Beta (m = 0.12%, sd = 0.086%, [A] = 0%, [B] = 100%) [24]
Efﬁcacy against A&E visits and hospitalisationsb
Dose 1 After 6 months 96% (90.2–98.8) Beta (m = 96%, sd = 2.8%, [A] = 18.9%, [B] = 99.2%) [8]
After 12 months 90.7% (85.6–94.3) Beta (m = 90.7%, sd = 2.5%, [A] = 10.9%, [B] = 98.6%) [8]
Dose 2 After 4 months 100% (81.8–100) Beta (m = 100%, sd = 2.5%, [A] = −115%, [B] = 100%) [8]
After 10 months 92.2% (65.6–99.1) Beta (m = 92.2%, sd = 9.4%, [A] = 0.6%, [B] = 99.1%) [8]
Efﬁcacy against GP consultationsb
Dose 1 After 6 months 87.3% (80.3–92.0) Beta (m = 87.3%, sd = 3.0%, [A] = −0.3%, [B] = 99.4%) [8]
After 12 months 79.4% (73.4–84.1) Beta (m = 79.4%, sd = 2.7%, [A] = −0.8%, [B] = 99.7%) [8]
Dose 2 After 4 months 91.8% (84.0–96.3) Beta (m = 91.8%, sd = 3.2%, [A] = −1.2%, [B] = 99.5%) [8]
After 10 months 76.2% (63.0–85.0) Beta (m = 76.2%, sd = 6.0%, [A] = 3.2%, [B] = 97.4%) [8]
Relative risk of vaccine-related intussusception vs background rate
Dose 1 1–7 days 6.76 (2.40–19.01) Lognormal (m = ln(6.76), sd = 0.53) [23]
8–21 days 3.45 (1.33–8.94) Lognormal (m = ln(3.45), sd = 0.49) [23]
Dose 2 1–7 days 2.84 (1.10–7.34) Lognormal (m = ln(2.84), sd = 0.48) [23]
8–21 days 2.11 (0.97–4.62) Lognormal (m = ln(2.11), sd = 0.40) [23]
a Weekly age distributions were ﬁxed for each run. A gamma distribution was used for both intussusception admissions (mean 30.8, standard deviation 14.2 and shift
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b Efﬁcacy values are ﬁtted to the two points of follow-up using a sigmoid lognorm
accination; t, time in weeks since vaccination; d, mean duration of protection, sd =
ustralia, than in Mexico or Brazil. In the USA one additional case of
accine-related intussusception has been reported for every 18,713
nfants vaccinated based on 207,955 doses of Rotarix® monitored
hrough the Vaccine Safety Datalink (VSD). Because very few infants
re unvaccinated in this monitoring system, a rapid cycle analysis
s used to establish whether the intussusception incidence exceeds
 critical value, and conﬁdence limits are not available [13]. The
verall estimate of risk from Australia is very similar: one vaccine-
elated intussusception in every 20,000 vaccinated infants (95% CI:
,000–53,000) based on a self-controlled case-series analysis [23].
o evaluate the potential risk of vaccine-related intussusception in
ngland, estimates of relative risk (RR) are needed for the different
eriods of risk following each dose. The Australian estimates of RR
ere used for this analysis (Table 1).
We assumed a case fatality ratio (CFR) of 0.12% (95% CI:
.02–0.34%) based on three intussusception deaths reported among
588 cases identiﬁed in nine studies across seven European
ountries [24].
.2. Estimated beneﬁts of Rotarix® (RVGE events prevented)
For estimates of Rotarix® vaccine impact, RVGE events included
P consultations, visits to A&E and admissions in children aged <5
ears. In brief, the number of RVGE events in each week of age
ollowing Rotarix® vaccination was calculated as follows:
w × (1 − ((C2w × E2w) + (C1w − C2w) × E1w)))
here Rw, number of RVGE events in week of age; E1w, partial (1
ose) vaccine efﬁcacy in week of age, adjusted for waning since vac-
ination; E2w, full (2 dose) vaccine efﬁcacy in week of age, adjusted
or waning since vaccination; C1w, coverage of dose one in week
f age, adjusted for age restriction scenario; C2w, Coverage of dose
wo in week of age, adjusted for age restriction scenario.n 10.75 and 3 years respectively, of hospital episode statistics.
cay curve i.e. VE × (1 − LOGNORMDIST(t,d,sd) where: VE, vaccine efﬁcacy at time of
ard deviation duration of protection.
The baseline number of RVGE events was updated to the year
2012 using a mid-year population of 3,393,400 (<5 yrs) in England
[18]. Each of these outcomes was converted into a weekly age dis-
tribution (gamma  distribution with mean 70.7, standard deviation
36.6, and zero shifted 8.26) ﬁtted to 39,966 laboratory-conﬁrmed
rotavirus cases detected in England and Wales between January
2005 and December 2007 [25].
For vaccine efﬁcacy after 1 and 2 doses, during year 1 and year
2 post-vaccination, we used results reported in a randomised con-
trolled trial of Rotarix® in six European countries: Czech Republic
(n = 299), Finland (2890), France (146), Germany (289), Italy (25),
and Spain (345) [8]. A sigmoid (reverse S) shape curve was ﬁtted to
year one and year two  efﬁcacy to account for waning levels of pro-
tection with time post-vaccination. To estimate overall efﬁcacy in
each age slice, a decay matrix was  used to account for the variation
in age at vaccination and waning protection with time.
A dynamic transmission model [26] assuming 91% coverage and
realistic mixing patterns estimated that herd effects would account
for only 3% of the total reduction in RVGE cases across all ages in
England. Indirect effects were therefore excluded from this analy-
sis.
Weekly coverage rates and age restrictions were applied to the
base case scenario as described above.
2.3. Risk beneﬁt analysis
10,000 probabilistic (Monte Carlo) simulations were run using
the parameters and distributions deﬁned in Table 1; each run
reported the expected number of RVGE GP consultations, A&E visits,
admissions and deaths prevented, as well as the estimated num-
ber of intussusception admissions and deaths caused. In addition,
the risk ratios (infants vaccinated per additional intussusception;
admissions/deaths prevented per additional intussusception) were
A. Clark et al. / Vaccine 32 (2014) 3604–3610 3607
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Fig. 1. Base case estimate of excess intussusception cases e
enerated for each simulation. The median, 5th and 95th percentile
f the 10,000 runs was calculated for all outcomes of interest.
We also evaluated the potential risks and beneﬁts of removing
he age restriction in England. Because information about the rel-
tive risk of vaccine-related intussusceptions is based on infants
accinated according to strict age restrictions (<15 weeks for dose
ne, <24 weeks for dose two), we ran two possible variants of an
nrestricted scenario: one assuming the same RR in all ages, and
he second assuming a two-fold increase in RR after 15 weeks for
ose one and after 24 weeks for dose two.
. Results.1. Estimated risks of Rotarix®
With strict adherence to recommended age restrictions, intro-
uction of Rotarix® could potentially cause 35 (7–98) additional
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otaShield® in the USA.ear in England following introduction of Rotarix® vaccine.
intussusception cases in children aged <5yrs in England each
year (Fig. 1). Without vaccination around 248 intussusception
admissions are expected each year in children aged <2 years; with
Rotarix® this is estimated to increase by 14% to 284. The number
of excess cases associated with dose one and dose two  was similar;
dose two  had a smaller relative risk but is administered when the
background rate of intussusception is higher. The overall risk esti-
mate is expected to be around one vaccine-related intussusception
in every 18,551 vaccinated infants (6728–93,952). The lower limit
for the range of risk associated with RotaShield® vaccine in the
USA was  one in 10,000 infants; for Rotarix® in England, less than
15% of the 10,000 Monte Carlo runs were within this range (Fig. 2).3.2. Estimated beneﬁts of Rotarix®
We estimate the introduction of Rotarix® could potentially pre-
vent around 74,000 GP consultations, 27,000 A&E visits, 13,000
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Table 2
Estimated annual risks and beneﬁts of Rotarix® introduction in England.
Infants within age window Infants outside age window
Constant RR with age Two-fold RR outside windowb
Median 5th and 95th pc. Median 5th and 95th pc. Median 5th and 95th pc.
Number of infants vaccinated with 2
doses
656,457 – 21,836 – 21,836 –
Risks  (Intussusception outcomes caused)
Admissions (Dose 1) 19.2 (5.1, 51.7) 1.3 (0.4, 3.5) 2.4 (0.8, 6.1)
Admissions (Dose 2) 16.2 (1.9, 45.9) 0.7 (0.1, 1.9) 5.2 (2.2, 11.8)
Admissions (Total) 35.4 (7.0, 97.6) 2.0 (0.4, 5.4) 7.6 (3.1, 17.9)
Deaths 0.03 (0.00, 0.16) 0.00 (0.00, 0.01) 0.01 (0.00, 0.03)
Beneﬁts (RVGE outcomes prevented)
GP visits 73,844 (66,422, 81,351) 1,701 (1497, 1902) 1701 (1497, 1902)
A&E  visits 27,395 (22,220, 32,743) 678 (542, 830) 678 (542, 830)
Admissions 13,276 (12,255, 14,181) 333 (277, 368) 333 (277, 368)
Deaths 2.86 (1.66, 4.10) 0.07 (0.04, 0.10) 0.07 (0.04, 0.10)
Risk  ratioa
N vaccinated per excess IS admission 18,551 (6728, 93,952) 11,089 (4048, 50,793) 2,863 (1223, 7,156)
Risk-beneﬁt ratioa
RVGE admissions prevented per
excess IS admission
375 (136, 1900) 169 (62, 775) 44 (19, 109)
RVGE  deaths prevented per excess IS
death
88 (18, 852) 39 (8, 358) 9.6 (2.4, 54)
e Carlo simulation runs; deriving them from the summary statistics may therefore give
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dmissions and 3 deaths in children aged <5 years, each year in
ngland (Table 2). This is equivalent to savings of over £11 million
er year based on previously published average costs of £26 per GP
onsultation, £56 per A&E visit and £612 per admission [5].
.3. Risk-beneﬁt of Rotarix®
During a single year with vaccination, we estimate that there
ould be 13,276 (12,255–14,181) fewer RVGE admissions and 35
7–98) more intussusception admissions (Figs. 3 and 4). There
ould be 375 (136–1,900) fewer RVGE admissions for every addi-
ional vaccine-related intussusception admission. There would be
8 (18–852) fewer RVGE deaths for every additional intussuscep-
ion death (Table 2).
.4. Risk-beneﬁt of removing Rotarix® age restrictionsRemoving the age restriction would allow an additional 21,836
nfants (3% of the birth cohort) to be vaccinated, and the result
ould be 1701 fewer GP consultations, 678 fewer A&E visits and
300250200150100500-50
Vacc ine-related intuss ucepon admiss ions caused
Fig. 4. Probabilistic sensitivity analysis to show annual intussusception admissions
caused and RVGE admissions prevented by Rotarix® vaccination in England.
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33 fewer admissions each year. However, the risk among this sub-
roup would be around one additional intussusception in every
1,089 vaccinated infants and could be as high as one in every 2863
with a two-fold increase in the RR outside of the age window).
mong this subgroup 44–169 RVGE admissions could be prevented
or every additional intussusception admission, and 10–39 RVGE
eaths could be prevented for every additional intussusception
eath (Table 2).
. Discussion
Our analysis suggests a potential risk of one vaccine-related
ntussusception in every 18,551 vaccinated infants, equivalent
o 35 additional intussusception admissions each year. We  esti-
ate that Rotarix® would prevent around 74,000 GP consultations,
7,000 emergency visits and 13,000 admissions each year. This is
quivalent to undiscounted savings of over £11 million annually.
here would be 375 fewer RVGE admissions for every additional
ntussusception admission, and 88 fewer RVGE deaths for every
dditional intussusception death. Lifting the age restriction policy
ould allow an additional 21,836 infants to receive the beneﬁts
f Rotarix® vaccination, but the risk of intussusception among this
ubgroup would be higher (one in every 2863–11,089 vaccinated
nfants) and the risk-beneﬁt ratio less favourable; in a pessimistic
cenario (assuming a two-fold increase in the RR outside of the
ge window) for infants in this subgroup, only 44 RVGE admis-
ions could be prevented for every one intussusception admission
aused, and ten deaths prevented for every one intussusception
eath caused.
This is the ﬁrst risk-beneﬁt analysis of a Rotavirus vaccina-
ion programme in Europe and provides important reassurance
or the recently introduced national immunisation programme.
he analysis uses detailed information on the weekly age distri-
ution of vaccination, intussusception and RVGE admissions in
nglish infants and is supplemented by good quality information
rom other high-income settings. Indeed, one of the strengths of
his analysis is that we are able to use the experience in other
igh income countries to inform the potential situation in England
efore local data become available. The recent Australian RR esti-
ates were used; the overall risk ratios for the USA and Australia
re similar but the Australian data cover a larger risk period (1–21
ays) and include 95% conﬁdence intervals. Monte Carlo simula-
ions were run to assess the implications of the uncertainty in the
nputs used. In particular, the risk-beneﬁt ratio for deaths is highly
ensitive to the CFR used for cases of intussusception. It was  nec-
ssary to pool the information from several European studies to
btain a reasonably robust sample size. We  used a pooled estimate
3 deaths from 2588 cases) based on studies that were conducted
n the United Kingdom and six other countries (Austria, Germany,
reland, Russia, Spain and Turkey). This estimate could be biased
n either direction; on the one hand the denominator is likely to
nclude readmissions for the same infants, on the other hand, in
t least one of the three deaths there were other complications
ikely to have contributed to the child’s death [14]. The relatively
ow CFR is however consistent with recent estimates from the USA
hich have ranged from 0 to 0.2% between 2000 and 2009 [27]. The
ncidence rate for intussusception cases was based on primary diag-
osis codes to avoid the potential inclusion of historical cases that
ere listed as a secondary diagnosis; this excluded around 6% of
dmissions <2 years. The ﬁgure of 187 primary diagnoses reported
n children aged <12 months was similar to the 190 admissions aged
12 months reported by a separate prospective, active surveillance
tudy in the year 2008/9 [22].
A recent risk-beneﬁt analysis in the USA reported 1093 RVGE
dmissions prevented for every one additional intussusception
dmission and 77 RVGE deaths prevented for every additional (2014) 3604–3610 3609
intussusception death [28]. We  estimated fewer RVGE admissions
prevented per additional intussusception admission. However our
analysis was based on risk evidence from Australia so accounted
for risk associated with the second dose and also accounted for risk
in the 8–21 day period after vaccination [28].
The estimated beneﬁts of Rotarix® vaccination would greatly
exceed the potential risk. However, national-level policy makers
must take into consideration more than the ‘greater good’ of one
vaccine in isolation. There are other criteria to be considered, and
any suggestion that a vaccine might have adverse effects is a mat-
ter of great sensitivity, perhaps most importantly because of the
potential consequences of negative press on the coverage of other
vaccines which target more serious diseases such as meningitis.
In England, concerns about the safety of whole-cell pertussis and
MMR (measles mumps  and rubella) vaccines have previously led
to sharp falls in programme coverage [29]. The level of risk that
prompted withdrawal of RotaShield® from the USA in 1999 was
one in every 5000–10,000 vaccinated infants. With over ten deaths
and many hospital admissions due to rotavirus each year in the USA,
some argued that the beneﬁts of RotaShield® greatly exceeded this
small-elevated risk [30]. Indeed the risk of serious adverse events
associated with Ibuprofen, a common over-the-counter medica-
tion used to treat infants, is also estimated to be around one in
every 10,000 [31]. The USA were the ﬁrst to introduce RotaShield®
so no post-licensure evidence existed elsewhere in the world at the
time of its withdrawal. In contrast, a large amount of post-licensure
evidence now exists for the second generation vaccines. The contin-
ued use of the second generation rotavirus vaccines in Australia, the
USA and other countries where an elevated risk has been reported,
demonstrates that a risk of one in every 20,000 is considered to be
acceptable in those settings. A face-to-face survey among 260 par-
ents in three US cities (Columbus, Denver, Knoxville) suggested an
intussusception risk of one in every 2174 vaccinated infants would
be acceptable to 90% of parents in the sample [32].
Both intussusception and severe RVGE are distressing illnesses,
but in high-income settings both are highly treatable acute condi-
tions of short duration. On the basis of mortality risk alone, Rotarix®
would be strongly favoured; in England, one rotavirus death could
be prevented every four months compared to one intussusception
death caused every 20–30 years. This takes little account of the
variation in mortality risk at the individual level but the risk of
death from both outcomes is extremely rare in England. In con-
trast, episodes of RVGE are very common and can be distressing
for both children and their parents. Finally, although the beneﬁts
of lifting the age restriction would still outweigh the risks, given
wider considerations the balance may  not be considered favourable
enough to alter the current recommendation in England for strict
adherence to the age restriction policy.
The risk of vaccine-related intussusception is yet to be deter-
mined in England and will not be available for some time.
Meanwhile our analysis provides preliminary estimates of the
potential risks and beneﬁts of the vaccine. The potential harmful
adverse effects of infant vaccination are understandably a highly
sensitive topic for parents and healthcare workers. The aim of this
analysis is not to create alarm about the, as yet undetected, level
of risk in England. Intussusception cases will need to be monitored
closely over the coming months. However, our analysis suggests
the beneﬁts of Rotarix® vaccination are likely to far exceed any
potential risk.
FundingAC and CS were commissioned by WHO’s  Initiative for Vaccine
Research (Vaccine Schedules Initiative) to develop a multi-country
model for evaluating the risks and beneﬁts of Rotavirus vaccines.
The analysis is based on the principles established during this work.
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